Table of Contents Author Guidelines Submit a Manuscript
International Journal of Hepatology
Volume 2011, Article ID 791013, 5 pages
http://dx.doi.org/10.4061/2011/791013
Case Report

Liver Resection after Downstaging Hepatocellular Carcinoma with Sorafenib

1Department of Digestive Surgery and Liver Transplantation, Rangueil Hospital, 1 avenue du Professor Jean Poulhès, 31059 Toulouse Cedex 9, France
2Department of Pathology, Rangueil Hospital, 31059 Toulouse, France
3Department of Hepato-Gastro-Enterology, Pau Hospital, 4 Boulevard Hauterive, 64046 Pau, France
4Department of Radiology, Rangueil Hospital, 31059 Toulouse, France

Received 20 October 2010; Accepted 24 January 2011

Academic Editor: Ryosuke Tateishi

Copyright © 2011 L. Barbier et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. M. Llovet, S. Ricci, V. Mazzaferro et al., “Sorafenib in advanced hepatocellular carcinoma,” The New England Journal of Medicine, vol. 359, no. 4, pp. 378–390, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. A.-L. Cheng, Y.-K. Kang, Z. Chen et al., “Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial,” The Lancet Oncology, vol. 10, no. 1, pp. 25–34, 2009. View at Publisher · View at Google Scholar
  3. V. Mazzaferro, E. Regalia, R. Doci et al., “Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis,” The New England Journal of Medicine, vol. 334, no. 11, pp. 693–699, 1996. View at Publisher · View at Google Scholar · View at PubMed
  4. M. Kudo, S. Kubo, K. Takayasu et al., “Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 Revised Version),” Hepatology Research, vol. 40, no. 7, pp. 686–692, 2010. View at Publisher · View at Google Scholar · View at PubMed
  5. M. Kudo, “Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice,” International Journal of Clinical Oncology, vol. 15, pp. 242–255, 2010. View at Google Scholar
  6. V. Boige, J. C. Barbare, and O. Rosmorduc, “Use of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma: PRODIGE AFEF recommendations,” Gastroenterologie Clinique et Biologique, vol. 32, no. 1, pp. 3–7, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. F. Thibault, H. Izzedine, V. Sultan et al., “Regression of vena cava tumour thrombus in response to sorafenib,” Progres en Urologie, vol. 18, no. 7, pp. 480–482, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. M. Kudo and K. Ueshima, “Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan,” Oncology, vol. 78, supplement 1, pp. 154–166, 2010. View at Publisher · View at Google Scholar · View at PubMed
  9. F. Bathaix, D. Marion, M. Cuinet et al., “Markedly effective local control of hepatocellular carcinoma with a poor prognosis by combined multimodal therapy with sorafenib as a neoadjuvant approach,” Gastroenterologie Clinique et Biologique, vol. 34, no. 4-5, pp. 314–318, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. P. A. Vagefi and R. Hirose, “Downstaging of hepatocellular carcinoma prior to liver transplant: is there a role for adjuvant sorafenib in locoregional therapy?” Journal of Gastrointestinal Cancer, vol. 41, no. 4, pp. 217–220, 2010. View at Publisher · View at Google Scholar · View at PubMed
  11. J. Bruix and J. M. Llovet, “Major achievements in hepatocellular carcinoma,” The Lancet, vol. 373, no. 9664, pp. 614–616, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Horger, U. M. Lauer, C. Schraml et al., “Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib,” BMC Cancer, vol. 9, article 208, 2009. View at Publisher · View at Google Scholar · View at PubMed